This review will discuss the role of angiogenesis in specific cutaneous diseases. Scientific evidence now points to the role of angiogenesis in tumor development and many other cutaneous disorders. Angiogenesis is a complex process that involves angiogenic growth factors and inhibitors, many of which could be a potential target for pharmacologic intervention. Antiangiogenic agents have recently been applied to dermatologic diseases with promising efficacy. (J Am Acad Dermatol 2009;61:945-58.)

Learning objectives: After completing this learning activity, participants should be able to recognize cutaneous diseases where angiogenesis is likely to be an important factor, recognize scenarios where angiogenic therapy may be useful in conjunction with traditional therapies, and be able to use angiogenic-mediating agents in the treatment of dermatologic disease.

Key words: angiogenesis; antiangiogenic agents; dermatology.

Angiogenesis in cutaneous disease: Part II

Vivian Laquer, BS,a Van Hoang, BS,c Amy Nguyen, MD,b and Kristen M. Kelly, MDb,c

New York, New York, and Irvine, California

ANGIOGENESIS IN CUTANEOUS DISEASE

Squamous cell carcinoma

Key points
• SCC has been associated with altered levels of angiogenic factors
• Most SCCs are best treated with traditional surgical methods, but there are a small number of cases with aggressive recurrent or metastatic disease for which additional treatment could be considered
• Case reports and an ongoing clinical trial are evaluating the use of antiangiogenic therapy for aggressive SCC

The epithelial cancer SCC has been noted to contain increased angiogenic growth factors, and there are some reports of treatment using antiangiogenic agents. Larcher et al2 used a mouse SCC model in which keratinocytes were transduced with a retrovirus carrying v-H-ras and their results showed highly increased vascular endothelial growth factor (VEGF) mRNA levels. Inhibiting this oncogene signal transduction pathway reduced VEGF production and resulted in smaller tumors in these mice.3 Thrombospondin-1 (TSP-1) has been reported to be down-regulated in cutaneous SCC, and the overexpression of TSP-1 in two stable transfected SCC cell lines inhibited tumor growth in vivo.4 These results conflict with those of Castle et al,5 who found that subcutaneous inoculation of athymic mice with human SCC cell lines
transfected with TSP cDNA antisense expression vector reduced TSP production and inhibited tumor growth.

Although most primary cutaneous SCCs have a high clinical cure rate, the small subset of cancers that recur or metastasize has a poor prognosis. Epidermal growth factor receptor (EGFR) has been shown to be overexpressed in metastatic cutaneous SCC, and cetuximab has been used for the treatment of aggressive or metastatic disease. At this time, there are only case reports in the literature, but a phase II trial is underway. A single case report noted repeated responses to cetuximab in a patient with an inoperable, rapidly growing cutaneous SCC with strong human EGFR expression. Cetuximab was administered intravenously (IV) at a loading dose of 400 mg/m², followed by weekly infusions of 250 mg/m². After the seventh weekly dose, a complete clinical response was achieved. Discontinuation of infusions resulted in recurrence. Additional infusions achieved tumor response, but the patient became refractory to treatment and died. Bauman et al reported excellent responses in two cases of elderly patients with extensive cutaneous SCC recurrence treated with palliative cetuximab (150 or 250 mg/m²). Complete clinical clearance was achieved and responses were maintained at last reported follow-up, 5 months after the initiation of treatment. A patient with oropharyngeal carcinoma that had a cutaneous SCC metastasis with overexpression of EGFR still had a fatal outcome 3 months after the initial diagnosis of cancer, in spite of chemotherapy and treatment with cetuximab.10

Ramadan et al reported the complete clinical clearance of cutaneous SCC in a patient with multiple myeloma. The patient developed a moderately differentiated SCC on the left temple. He was started on bortezomib (1.3 mg/m² IV on days 1, 4, 8, and 11) to improve his hematologic status before proceeding to SCC surgery. Bortezomib not only stabilized the myeloma but, unexpectedly, the SCC regressed and eventually disappeared, with complete healing of the skin occurring several months after the discontinuation of bortezomib. There was no evidence of recurrence of his SCC, even after he succumbed to multiple myeloma 1 year later.

Fibrohistiocytic tumors

Key point

- Malignant fibrohistiocytomas have increased expression of angiogenic factors as compared to dermatofibroma and dermatofibrosarcoma protuberans

Koga et al used immunohistochemistry to look at levels of hypoxia-inducible factor (HIF)-1α expression in various fibrohistiocytic tumors. They found significantly higher levels in malignant fibrous histiocytoma compared to dermatofibroma and dermatofibrosarcoma protuberans. Furthermore, cases of malignant fibrohistiocytomas expressing high levels of HIF-1α showed greater angiogenesis (as measured by microvessel density) than those with low levels of HIF-1α. Increased HIF-1α expression and angiogenesis may be associated with the malignant potential of fibrohistiocytic tumors.

Malignant melanoma

Key points

- Malignant melanoma (MM) has been associated with increased levels of many angiogenic factors
- Antiangiogenic agents have shown potential efficacy for the treatment of MM
- Antiangiogenic agents appear to be most effective for MM when used in combination with chemotherapy

MM is a cancer of melanocytes, and dermatologists are familiar with the deadly potential of this disease. Angiogenic growth factors are up-regulated in melanoma cells and there are studies of successful treatment of melanoma using antiangiogenic therapies, especially when used in combination with cytotoxic therapies.

Angiogenesis mediators are increased in human melanoma cell lines. Several studies have demonstrated an increase in VEGF, basic fibroblast growth factor (bFGF), platelet-derived growth factor
(PDGF)-AB, interleukin (IL)-8, and transforming growth factor-beta (TGFβ). The transfection of nonmetastatic and IL-8–negative melanoma cells with the IL-8 gene produced highly malignant and invasive tumors in mice. Overproduction of VEGF and its receptors VEGFR1 and VEGFR2 was shown in melanoma xenografts, and treatment with phosphatidylinositol 3-kinase (PI3 K)–specific inhibitors reduced the survival of these tumor cells. Akt was shown to be overexpressed in mice models during the transformation of melanoma cells from the radial to vertical growth phases. Activated Akt expression was shown to be increased in Spitz nevi and melanomas as compared with benign intradermal nevi. Akt production may protect melanoma cells from apoptosis and make them less responsive to chemotherapy and radiation. Using a microarray analysis, one study showed that patients with strong phosphorylated Akt expression in their melanoma tissue, along with weak expression of p53 up-regulated modulator of apoptosis, had a lower 5-year survival rate. Using Akt/protein kinase B signaling inhibitors, a small-molecule Akt inhibitor, reduced melanoma cell survival in a dose- and time-dependent manner. Mammalian target of rapamycin (mTOR) activation is also strongly associated with MM compared to benign melanocytic lesions.

Endostatin levels were elevated in stage III and stage IV melanoma patients compared to healthy control individuals, and endostatin levels might have a utility for disease monitoring. Animal studies revealed the efficacy of recombinant endostatin to suppress melanoma tumor growth and melanoma metastasis formation. The clinical usefulness of endostatin remains uncertain, because a phase II clinical trial evaluating endostatin alone and in combination with interferon-alpha2b (IFNα2b) showed no antitumor response. Recent studies have shown some efficacy using antiangiogenic agents for metastatic melanoma, especially when used in combination with chemotherapy. Bevacizumab has been used in several trials. Twelve patients were administered paclitaxel 70 mg/m\(^2\) weekly and bevacizumab 10 mg/kg IV biweekly for five consecutive weeks every 6 weeks. Cycles were repeated until disease progression or treatment intolerance. Two patients achieved a partial response for 5.6 and 3.9 months, respectively. Eight patients, whose tumors were growing at the time of treatment, experienced disease stabilization for a median of 4 months (range, 2.8-8.8 months), and two patients had progressive disease despite treatment. In a randomized phase II trial, bevacizumab (15 mg/kg IV every 2 weeks) was administered with and without daily low-dose IFNα2b (1 MU/m\(^2\) subcutaneously daily), an inhibitor of bFGF. Bevacizumab prolonged disease stabilization in about 25% of the patients (8/36); however low-dose IFNα2b did not augment the activity of bevacizumab. Bevacizumab (5 mg/kg) in combination with chemotherapeutic agents cisplatin/carboplatin or fotemustine achieved disease regression in two out of three patients after three courses of therapy. Longer follow-up was not provided.

Sorafenib has shown some effect for advanced melanoma. In a phase II clinical trial in advanced melanoma patients, sorafenib was well tolerated but had little or no antitumor activity when used as a single agent. Combination therapy has been more promising. A phase I trial combined sorafenib with carboplatin and paclitaxel in advanced melanoma patients and was able to induce one complete response and nine partial responses. In a phase II trial, oral sorafenib (400 mg twice a day) and IV dacarbazine (1000 mg/m\(^2\) on day 1 of a 21-day cycle) showed a 50% improvement in progression-free survival as compared to placebo plus dacarbazine. However, overall survival was not improved. Additional investigations are ongoing.

mTOR inhibitors have shown promise for melanoma treatment. Bevacizumab in combination with sirolimus caused the loss of half of the VEGFR2-positive melanoma cells in a culture study. Sirolimus was shown to inhibit the proliferation of MM cell lines, especially when combined with celecoxib, a cyclooxygenase 2 inhibitor. Combined treatment of six melanoma cell lines with sorafenib and sirolimus led to an approximately twofold increase of cell death compared with sorafenib alone. A study using human melanoma xenotransplants in mice did not show a significant antitumor effect from temsirolimus alone; however, temsirolimus in combination with dacarbazine reduced tumor weight compared to dacarbazine monotherapy. Another combination regimen using temsirolimus and cisplatin showed superior melanoma growth inhibition compared to monotherapies.

Other newer antiangiogenic therapies, including batimastat, marimastat, bortezomib, and ABT-510, have also been evaluated for use in melanoma. Batimastat was shown to inhibit metastatic spread and to delay tumor growth in murine melanomas. A phase II study of marimastat in MM showed a partial response in two of 28 patients, stable disease in five patients, and disease progression in 21 patients. Preclinical studies revealed bortezomib to be effective at inhibiting the in vitro growth of several human melanoma cell lines. A phase II study of bortezomib alone in the treatment of metastatic melanoma proved to be ineffective.
Bortezomib may achieve better results if used in combination with chemotherapeutic drugs. A phase II trial evaluating the clinical efficacy of ABT-510 in metastatic melanoma was terminated early because it did not demonstrate definite clinical efficacy.44 Again, combination therapy may be more effective.

**Cutaneous lymphoma**

**Key points**

- The mTOR pathway may play a major role in the pathogenesis of cutaneous lymphoma
- Sirolimus inhibited anaplastic large cell lymphoma growth in a cell culture study
- Bortezomib is being studied for the treatment of cutaneous lymphoma

Phosphorylated mTOR has been found in the nucleus of cutaneous anaplastic large cell lymphoma (ALCL) tumor cells, especially in cells undergoing mitosis. The expression of mTOR pathway proteins, including phosphorylated ribosomal protein S6 kinase, was detected in the cytoplasm of these cells.45 The mTOR pathway may influence cutaneous ALCL and sirolimus and other mTOR inhibitors may be useful therapeutic options. In an in vitro study of cell cultures, only sirolimus inhibited growth of cutaneous ALCL, as compared to cyclosporine A, FK-506 (tacrolimus), and prednisone.46 In a case study, primary ALCL refractory to 15 years of treatment with radiation and multiple chemotherapy regimens was successfully treated with oral sirolimus 2 mg/day in combination with radiation.45

Bortezomib has been studied in a phase II trial for treatment of cutaneous T-cell lymphoma and peripheral T-cell lymphoma with isolated skin involvement. In a study of 12 patients, two achieved complete remission and six achieved partial remission with results lasting 7 to 14 months or more.47

**Kaposi sarcoma**

**Key points**

- The KS herpesvirus is believed to induce angiogenesis via the PI3K/Akt pathway
- Sirolimus, imiquimod, and thalidomide are being evaluated as therapies for KS

KS is an angiogenic tumor thought to be caused by infection or reactivation of human herpes virus 8, also known as KS herpesvirus (KSHV). KSHV infection activates many endothelial cell signaling pathways, including PI3K/Akt. Montaner et al48 used primary human umbilical vein endothelial cells and showed that KSHV G protein–coupled receptor expression potently induces the kinase activity of Akt. GPCR was found to increase VEGF secretion by stimulating HIF-1α to activate p38 and mitogen-activated protein kinase (MAPK).49

KSHV-GPCR also prevented the apoptosis of human umbilical vein endothelial cells that normally occurs with serum deprivation. This protection from apoptosis was not seen with use of wortmannin (an inhibitor of Akt) or in Akt-deficient mutants.50 In an animal model, transduction of the vGPCR gene played a critical role in inducing angioproliferative tumors very similar to human KS.50

Immunohistochemical staining did not find significant VEGF in KS lesions.51 However, Cornali et al52 found high amounts of VEGF mRNA and protein present in KS spindle cells. VEGF was also found when lesions were biopsied after photodynamic therapy (PDT).53 Bevacizumab was shown to enhance the responsiveness of KS to PDT.53

Several studies have shown the efficacy of sirolimus for the treatment of iatrogenic KS in renal transplant patients. Importantly, this treatment did not sacrifice the immunosuppression necessary to prevent organ rejection.54-56 In another case report involving KS in a patient on immunosuppressive therapy for pemphigus vulgaris, sirolimus (2 mg/day) eliminated KS lesions while still retaining adequate immunosuppression to control the pemphigus.57 Sirolimus was used in one immunocompetent patient with classic Mediterranean KS and achieved complete clinical, histologic, and immunohistochemical regression of 16 of 17 of the patient’s lesions.58

Imiquimod and thalidomide have also been used for treatment of KS.59,60 In a prospective, open-label, phase II clinical trial using imiquimod 5% cream to treat KS, eight of 17 patients showed clinical improvement of the lesions.60 Rubegni et al61 reported the treatment of three non-AIDS related–KS patients with thalidomide 100 mg/day. All experienced partial remission at 4 months, and two patients achieved complete remission at 12 months.

**Angiosarcoma**

**Key points**

- The up-regulation of VEGF has been noted in angiosarcomas
- Long-term remission has been demonstrated in a case report in which angiosarcoma was treated with radiation and bevacizumab

Angiosarcoma is a vascular tumor that has been shown to have up-regulation of VEGF. Bevacizumab, an antibody against VEGF, has been used for the treatment of angiosarcoma.62 Two patients had angiosarcoma of the nose and were treated with combination bevacizumab and radiotherapy before surgical resection. One patient was treated with a bolus infusion of bevacizumab 5 mg/kg every 2 weeks for a total of four doses, whereas the second
patient was treated with a bolus infusion of bevacizumab 10 mg/kg every 2 weeks for a total of three doses. Pathologic evaluation showed no residual angiosarcoma, and both patients remained recurrence free at the time of final reported evaluation (8.5 months for one, 26 months for the other).

**Hemangiomas**

**Key points**

- Angiogenic factor expression changes as hemangiomas progress from proliferative to involuting phases
- Topical imiquimod has been used to treat infantile hemangiomas, but results are variable with a recent study indicating limited efficacy

Hemangiomas are the most common benign tumor of newborns, affecting approximately 10% of all infants. Infantile hemangiomas are characterized by early proliferation of endothelial cells in the first year of life, followed by spontaneous involution. Angiogenic markers have different expression patterns during the various infantile hemangioma stages. In the proliferative phase, high expression of proliferating cell nuclear antigen, type IV collagenase, and VEGF were noted by Takahashi et al. In the involuting phase, they noted elevated expression of tissue inhibitors of metalloproteinases (TIMP). Expression of bFGF, urokinase, CD31, von Willebrand factor, and SMC-actin were present in both proliferating and involuting phases. Interestingly, many endogenous angiogenesis suppressors, including TIMP-1 and IFNα, were unregulated in the involuting and involuted phases as compared to the proliferative phase. Yu et al. studied hemangioma-derived endothelial cell cultures and found an increase in mRNA expression of angiopeptin-1 (Ang1) and Tie2 and a down-regulation of Ang2. Giatromanolaki et al. used immunohistochemistry in 25 cutaneous capillary hemangiomas (phase not specified) and noted increased expression of VEGF and HIF-2α, but not HIF-1α. Ritter et al. showed increased insulin-like growth factor (IGF)-2 and integrins in hemangiomas using microarray analysis.

Both endogenous and exogenous angiogenesis inhibitors have been used successfully to reduce experimentally induced hemangioma tumor growth. Daily injections of batimastat into murine hemangiomas resulted in delayed tumor growth but not tumor eradication. Other inhibitors including TIMP-2, VEGF toxin conjugate, and synthetic compound TNP-470 (fumagilin derivative) have also reduced tumor growth in early experimental hemangioma models.

There are multiple reports of treatment of infantile hemangiomas with a short course of topical imiquimod 5% cream. Martinez et al. reported the successful use of topical imiquimod applied three times a week to treat two patients with infantile hemangiomas. Welsh et al. applied topical imiquimod 5% cream five times a week to infantile hemangiomas and achieved complete resolution or excellent improvement in seven out of 10 patients. Hazen et al. reported a case report of a chest wall hemangioma that resolved after 10 weeks of topical imiquimod therapy. One retrospective study showed complete regression and resolution in infantile hemangiomas after treatment with imiquimod 5% cream; superficial lesions (as compared to mixed or deep lesions) were the best responders. The most common side effect was crusting and irritation, and no systemic toxicity was noted. Despite these promising results, a recent study indicates that imiquimod therapy may not be as beneficial for the treatment of hemangiomas as previously thought. A phase II study in sixteen infants in which imiquimod was applied three to seven times a week for 16 weeks to hemangiomas showed improvement in only superficial coloration, while lesion size remained unaffected.

Arbiser recently reported use of eosin 2% solution applied three times a day unoccluded for hemangiomas with superficial ulcers and once a day under hydrocolloid wound dressing for hemangiomas with deep ulcers. Duration of application ranged from 3 to 14 weeks. Of the 21 ulcers, 16 healed completely without recurrence and 5 required additional types of therapy. Arbiser reports that eosin inhibits production of Ang2 in endothelial cells and ulceration in hemangiomas may be a result of imbalance between Ang2 and VEGF. Another recent study used propranolol for the treatment of aggressive hemangiomas of infancy. Inhibition of endothelial cell VEGF production was proposed as a mechanism, but further evaluation will be required.

**Hemangioendotheliomas**

**Key point**

- Antiangiogenic treatment has been experimentally used for treatment of hemangioendotheliomas

Hemangioendotheliomas are rare vascular tumors characterized by an epithelioid endothelial cell proliferation. They were named because their aggressiveness falls between benign hemangiomas and aggressive angiosarcomas. Antiangiogenic agents have been investigated for therapy. Angiostatin and recombinant endostatin were shown to inhibit
vascular malformations. In experimentally induced hemangioendotheliomas, the application of imiquimod 5% cream significantly decreased tumor growth. These tumor cells showed decreased proliferation, increased tumor apoptosis, increased expression of TIMP-1, and decreased activity of matrix metalloproteinase (MMP)-9.

Although antiangiogenic therapy for hemangioendotheliomas is not currently considered the standard of care, there are a number of case reports that show promising results. Belmont et al reported a nonresponsive pulmonary epithelioid hemangioendothelioma that was treated with a combination of carboplatin—paclitaxel and bevacizumab (15 mg/kg and 450 mg, respectively) for five cycles followed by bevacizumab alone for a total of 13 cycles. The patient showed stabilization and significant clinical improvement was maintained at 13 months after initiation of treatment. Another patient with a non-resectable hepatic epithelioid hemangioendothelioma with extensive pulmonary metastases was successfully treated with thalidomide 200 mg/day. Serial computed tomography scans showed no disease progression over a 3-year period; after 3 years, the patient was switched to thalidomide 100 mg/day and remained asymptomatic.

**Vascular malformations**

- **Key points**

  - Multiple angiogenic factors that are overexpressed in vascular tumors are not present in vascular malformations
  - Antiangiogenic agents may have a role in treatment of these lesions when combined with other treatment modalities, such as laser therapy

Vascular malformations are not proliferating tumors but, rather, result from inborn errors of vascular morphogenesis. Multiple cellular makers that are seen in vascular tumors such as VEGF, bFGF, type IV collagenease, and urokinase are not present in vascular malformations. The overexpression of Akt1 in murine endothelial cells resulted in the initiation of treatment. Akt has also been linked to vascular malformations in specimens of mice endothelial cells and biopsies from patients with Sturge–Weber syndrome.

Although vascular malformations are not proliferating, antiangiogenic therapy may still play a role in therapeutic management. Our group and others have looked at the use of combination selective photothermolysis and antiangiogenic therapy for the treatment of port wine stain (PWS), a capillary vascular malformation. Currently, the standard of treatment for PWS is the pulsed dye laser (PDL). Complete lesion blanching is disappointing, occurring in less than 20% of patients treated with PDL. In a wound healing response, inflammatory cells migrate into the area secreting cytokines that are potent up-regulators of HIF-α and VEGF. The PDL-induced wound healing response may lead to new vessel formation. Phung et al showed that normal skin treated with a combination of PDL and daily topical application of sirolimus for 14 days showed a decrease in reformation and reperfusion of vessels as compared to skin treated with PDL alone. Kelly et al randomly assigned subjects with PWS to treatment protocols using either PDL plus imiquimod or PDL plus placebo. Treatment was well tolerated, and the average reduction in erythema measured by noninvasive reflectance measurements was greater in the PDL plus imiquimod group when compared to the PDL plus placebo group. These results indicated that application of an agent with antiangiogenic effects like imiquimod may improve the selective thermolysis–based treatment of cutaneous vascular lesions, including PWS. Chang et al reported similar results.

**Pyogenic granulomas**

- **Key points**

  - Pyogenic granulomas express many angiogenic factors
  - Topical imiquimod has been reported as a successful treatment for pyogenic granulomas

Pyogenic granulomas are common benign vascular lesions of the skin and mucosa. Some early studies in angiogenesis revealed that factors extracted from pyogenic granulomas could induce neovascular proliferation in the skin membrane of hamsters and could increase vascularity of normal skin samples grafted onto chick embryo chorioallantoic membranes. More recent studies have identified these angiogenic factors, which are likely to play an important role in the pathogenesis of pyogenic granuloma. Immunohistochemistry studies revealed that VEGF,
bFGF, Tie2, Ang1, Ang2, ephrin-B2, and Eph-B4 are up-regulated in pyogenic granulomas on human gingiva as compared to healthy gingiva.\textsuperscript{96,97} Moreover, the angiogenic inhibitor angiotatin was expressed significantly less in pyogenic granulomas.\textsuperscript{97} TIMPs were found to be up-regulated in stromal cells and in cells surrounding proliferating vessels of pyogenic granulomas.\textsuperscript{98} Shimizu et al\textsuperscript{99} noted the increased expression of inducible NO synthase, mainly in the endothelial cells of pyogenic granulomas.

There are many treatment options for pyogenic granulomas, but several studies used the antiangiogenic effects of imiquimod.\textsuperscript{100-104} Using imiquimod cream 5% daily, the resolution of facial pyogenic granulomas was seen in five of five children within 2 to 4 weeks.\textsuperscript{102} Side effects were minimal and only small mildly erythematous or hypopigmented macules remained after treatment. Imiquimod was also successful in treating pyogenic granulomas that were recurrent and resistant to other therapies.\textsuperscript{101,103,104}

**Angiofibromas**

**Key points**

- **Tuberous sclerosis complex mutations cause dysfunction of the tuberin/hamartin proteins, blocking inhibition of the mTOR pathway and resulting in abnormal growths and blood vessel proliferations**
- **Sirolimus has shown promise for the treatment of tuberous sclerosis–related tumors**

Tuberous sclerosis is an autosomal dominant disorder that results from gene defects in the tuberous sclerosis complex (TSC) genes 1 and 2, on chromosomes 9 and 16, respectively. Normally, TSC1 and 2 produce hamartin and tuberin complex proteins that are known to inhibit the mTOR pathway.\textsuperscript{105-107} TSC mutations cause dysfunction of the tuberin/hamartin proteins, blocking inhibition of the mTOR pathway and resulting in abnormal growths and blood vessel proliferations in several organs, including the skin. Characteristic cutaneous manifestations of tuberous sclerosis include facial angiofibromas.\textsuperscript{108} Facial angiofibromas are seen in 70% to 80% of patients. They may be disfiguring, and do not resolve without treatment.

Angiofibromas are characterized by the proliferation of vascular and interstitial cells that express angiogenic factors, including VEGF.\textsuperscript{109,110} Kenerson et al\textsuperscript{111} found elevated levels of phosphorylated mTOR and its effectors in primary renal tumors of TSC and found sirolimus to be an effective treatment in Eker rats that carry a germ line mutation of the TSC2 gene. A study using 0.4% and 0.8% topical sirolimus showed improved survival and reduced tumor growth in nude mice bearing subcutaneous TSC-related tumors.\textsuperscript{112} One case study reported dramatic improvement of angiofibromas in a patient with TSC using sirolimus for immunosuppression after renal transplant.\textsuperscript{113}

**Psoriasis**

**Key points**

- **Angiogenesis is thought to play a role in the dilated vasculature of the papillary dermis in psoriasis**
- **Sirolimus in combination with cyclosporine has been used to treat psoriasis**
- **Other antiangiogenic agents are currently being studied as treatments for psoriasis**

Psoriasis, characterized by erythematous, well demarcated, scaly plaques, is a chronic inflammatory disease of the skin. The underlying pathogenesis of psoriasis is a complex interplay of abnormal epidermal differentiation and proliferation and activation of the immune system. Angiogenesis appears to play a role in psoriasis pathogenesis, as shown by dilated and tortuous vessels in the papillary dermis. VEGF is known to be elevated in psoriatic skin.\textsuperscript{114,115} Transgenic delivery of VEGF to mouse skin resulted in a psoriasis-like inflammatory skin condition.\textsuperscript{116} Man et al\textsuperscript{117} found that calcium enhances VEGF and VEGFR expression in psoriatic epidermis. When VEGF expression was blocked by bevacizumab, calcium continued to enhance protein levels of VEGFRs independent of VEGF. In 2005, Krueger et al\textsuperscript{118} hypothesized that the dysfunction of TGFβ-mediated cellular immunity leads to the excessive production of proinflammatory cytokines, including tumor necrosis factor-alfa (TNFα), IL-2, interferon gamma (IFNγ), and TGFβ. TGFβ then stimulates keratinocytes to produce VEGF. Nickoloff et al\textsuperscript{119} showed that keratinocytes from psoriatic skin had a sevenfold reduction in TSP-1 production and addition of a highly purified TSP-1 suppressed the angiogenic activity in these keratinocytes.

Ang1, Ang2, and Tie2 have also been found to be up-regulated in psoriatic lesional skin.\textsuperscript{120} Ang1 is highly expressed by stromal cells in the papillary dermis of psoriatic skin and is proposed to help maintain and stabilize newly formed vessels.\textsuperscript{120,121} Ang2 is also expressed highly in the papillary dermis; however, its signal is limited to the endothelial cells.\textsuperscript{120} In one study, five psoriatic patients treated with psoralen plus ultraviolet A light phototherapy and two patients treated with tazarotene for 8 weeks resulting in clinical improvement were shown to
have decreased Ang1, Ang2, and Tie2 mRNA levels in involved skin.\textsuperscript{120}

Sirolimus has been used both systemically and topically to treat psoriasis. Although systemic sirolimus alone proved to be ineffective in treating severe psoriasis, it was used successfully in combination with subtherapeutic levels of cyclosporine in order to limit nephrotoxicity.\textsuperscript{122} Topically applied sirolimus has also shown some effect on plaque psoriasis, but response to topical steroids was better.\textsuperscript{123}

Neovastat has shown promising results in phase II studies for the treatment of psoriasis.\textsuperscript{124} There has also been one case report of a patient whose chronic cutaneous psoriasis improved after systemic therapy with the VEGFR-TK inhibitor, SU-011248, during monotherapy for treatment of renal cell carcinoma.\textsuperscript{125} In another case report, two weeks of daily topical application of dobesilate, a fibroblast growth factor inhibitor, significantly improved skin lesions in chronic plaque psoriasis.\textsuperscript{126}

**Rosacea**

**Key points**
- VEGF overexpression has been noted in rosacea
- Cathelicidins, antimicrobial peptides with known angiogenic and inflammatory properties, have been linked to rosacea
- Topical dobesilate has been reported to clinically improve rosacea

Rosacea is a common skin disease that has varied clinical presentations, including erythema and telangiectasia, papulopustules, phymomatous changes, and ocular symptoms. Rosina et al\textsuperscript{127} performed videocapillaroscopy on erythematotelangiectatic rosacea lesions and showed increased neoangiogenesis and blood vessel enlargement. Immunohistochemistry revealed increased VEGF expression in lesional versus nonlesional skin of rosacea patients.\textsuperscript{128} Smith et al\textsuperscript{129} showed expression of both VEGFR1 and 2 in rosacea vascular endothelium and infiltrating mononuclear cells.

Recently, cathelicidins with known angiogenic and inflammatory properties have been implicated in the pathogenesis of rosacea.\textsuperscript{130} Cathelicidins are antimicrobial peptides that are believed to directly kill microorganisms, participate in the innate immune system, and form a chemical shield of protection on the skin.\textsuperscript{130-132} LL-37 is the C-terminal part of the only human cathelicidin identified to date, called human cationic antimicrobial protein.\textsuperscript{133,134} LL-37 is expressed by polymorphonuclear leukocytes, lymphocytes, macrophages, and epithelial cells. LL-37 interacts with endothelial cells and stimulates angiogenesis both in vitro and in vivo.\textsuperscript{135} LL-37 modulates the expression of VEGF via HIF-1α in human keratinocytes. When compared to healthy skin, rosacea was found to have increased levels of LL-37 and other cathelicidin peptides that were posttranslationally modified to have increased protease activity.\textsuperscript{136}

Cuevas et al\textsuperscript{137} used topical dobesilate, an inhibitor of FGF, for the treatment of erythematotelangiectatic rosacea and reported improvement of erythema and telangiectasia after 2 weeks.

**Atopic dermatitis**

**Key point**
- Pathophysiology theories for AD include immune and barrier dysfunction, but angiogenesis may also play an important role

AD is a common, chronic inflammatory skin disease characterized by pruritus, eczematous lesions and lichenification. Pathophysiology theories for AD have focused on immune dysfunction or defective barrier function, but angiogenesis may also play an important role. An epidermal IL-4–transgenic mouse model was developed that closely resembles human AD clinically, histopathologically, serologically, bacteriologically, and immunologically.\textsuperscript{138-141} The dermal blood vessels in this mouse model show changes consistent with angiogenesis, including elongation, sprouting, and intussusception.\textsuperscript{142} Chen et al\textsuperscript{143} recently noted a progressive increase in blood vessel number, diameter, and percent dermal area occupied by CD31\textsuperscript{+} and VEGFR2 vessels as the disease evolves from start to a chronic state. They also reported an increase of transcripts of VEGF-A, Ang1, Ang2, guanylate-binding protein-1, and the endothelial cell adhesion molecule, vascular/endothelial-cadherin. IL-6 and IFNγ were thought to stimulate the VEGF-A mRNA production in the skin.\textsuperscript{143}

In human AD lesions, VEGF121, an isoform of VEGF-A that mainly regulates vascular permeability, was noted to be overexpressed in the stratum corneum.\textsuperscript{144} Groneberg et al\textsuperscript{145} hypothesized that participation of mast cells could underlie the neovascular processes in AD. They showed that there was migration of mast cells from the papillary dermis to the basal lamina in the epidermis, and these mast cells were localized close to endothelial cells. Mast cell density within skin tissues has been demonstrated to correlate with blood vessel density, and mast cells are thought to lead to the expression of proangiogenic factors.\textsuperscript{146} Endothelial cells were positive for CD105, a marker of vascular proliferation, and gene expression
profiling for angiogenic factors was positive for TNF-α, VEGF-B, IL-8, Ang1, Ang2, and some MMPs.\textsuperscript{144}

**Keloids**

**Key points**

- **Increased expression of angiogenic factors has been noted in keloids**
- **Sirolimus has been evaluated in a cell culture study as a possible therapeutic option for keloids**

Wu et al\textsuperscript{147} showed elevated expression of HIF-1α and VEGF in keloid tissue compared to normal skin. Ong et al\textsuperscript{148} also found elevated expression of VEGF in keloid scars and higher levels of mTOR. They cocultured keratinocytes and fibroblasts extracted from keloid scars and exposed the cell cultures to sirolimus (2 and 0.01 μg/mL). VEGF expression, cell cycle proteins, and extracellular matrix proteins were observed to be down-regulated in a dose-dependent manner.

**Diabetic ulcers**

**Key points**

- **Proangiogenic factors may be deficient in chronic diabetic ulcers**
- **Topical PDGF has been shown to improve healing of diabetic wounds**

A recent study showed an increase in Akt phosphorylation in wound margin keratinocytes in normal skin repair, with near absence of Akt phosphorylation and VEGF in chronic wounds of diabetic mice.\textsuperscript{149} Insulin is thought to contribute to VEGF release in wound healing through the Akt-mediated pathway.

Another study revealed a decrease in HIF-1α protein in the wound of leptin receptor–deficient diabetic mice as compared to nondiabetic mice. Reduction of HIF-1α resulted in decreased DNA-binding activity and decreased expression of HIF-1 target genes, including VEGF. Restoration of HIF-1α in these diabetic wounds restored expression of VEGF, enhanced angiogenesis, and accelerated wound healing. This supports the role of HIF-1α in wound healing. Reduced HIF-1α may contribute to impaired wound healing and may offer a therapeutic target.\textsuperscript{150}

The topical application of recombinant human PDGF on cutaneous wounds in diabetic rats showed accelerated reepithelialization, increased thickness of granulation tissue, and higher density of capillary buds.\textsuperscript{150} Recombinant human PDGF-BB has been studied extensively for the treatment of lower extremity ulcers. A recent randomized, prospective, blinded clinical trial of 922 patients found that the application of once-daily PDGF in combination with good wound care significantly improved healing in diabetic neurotrophic foot ulcers.\textsuperscript{151}

**CONCLUSION**

Angiogenesis research is proceeding rapidly, and scientists and clinicians are gaining a better understanding of the role of this process in normal and disease states. Angiogenesis plays an important role in a wide range of cutaneous diseases. Increased understanding of this important topic will result in better understanding of disease pathogenesis and may foster development and implementation of novel and effective dermatologic therapeutics.

We would like to gratefully acknowledge the input of Jack Arbisser, MD, Elizabeth Rugg, PhD, Chris Hughes, PhD, and Narineh Zohrabian, MD, who provided input for this manuscript or have helped guide our studies related to cutaneous angiogenesis.

**REFERENCES**

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Larcher F, Robles AI, Duran H, Murillas R, Quintanilla M, Cano A, et al. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 1996;56:5391-6.
3. Conti CJ. Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy. Oncologist 2002;7(suppl 3):4-11.
4. Streit M, Velasco P, Brown LF, Skobe M, Richard L, Riccardi L, et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999;155:441-52.
5. Castle V, Varani J, Filigie S, Prochownik EV, Dixit V. Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest 1991;87:1883-8.
6. Shimizu T, Izumi H, Oga A, Furumoto H, Murakami T, Ofuji R, et al. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology 2001;202:203-6.
7. Maubec E, Duvillard P, Velasco V, Crickx B, Avril MF. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous-cell carcinoma of the skin. Anticancer Res 2005;25:1205-10.
8. Suen JK, Bressler L, Shord SS, Warso M, Villano JL. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs 2007;18:827-9.
9. Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 2007;143:889-92.
10. Thariat J, Ahammad A, El-Naggar AK, Williams MD, Holsinger FC, Glisson BS, et al. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer 2008;112:2698-709.
11. Ramadan KM, McKenna KE, Morris TC. Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma. Lancet Oncol 2006;7:958-9.
12. Koga K, Nishimura N, Shishime M, Nakayama J, Iwasaki H. Microvessel density and HIF-1α expression correlate with malignant potential in fibrohistiocytic tumors. Eur J Dermatol 2005;15:465-9.

13. Westphal JR, Van’t Hulenaar R, Peek R, Willems RW, Crickard K, Crickard U, et al. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer 2000;86:768-76.

14. Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin-8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 2000;60:4932-8.

15. Schadendorf D, Dorn-Beineke A, Borelli S, Riethmüller G, Pantel K. Limitations of the immunocytochemical detection of isolated tumor cells in frozen samples of bone marrow obtained from melanoma patients. Exp Dermatol 2003;12:165-71.

16. Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 1999;67:12-8.

17. Graells J, Vinyals A, Figueras A, Llorens A, Moreno A, Marcoval J, et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3 K signaling. J Invest Dermatol 2004;123:1151-61.

18. Bedogni B, O’Neill MS, Bouley DM, Giaccia AJ, Denko NC, et al. Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 2004;64:2552-60.

19. Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest 2007;117:719-29.

20. Kantrow SM, Boyd AS, Ellis DL, Nanney LB, Richmond A, Shyr Y, et al. Expression of activated Akt in benign nevi, Spitz nevi and melanomas. J Cutan Pathol 2007;34:593-6.

21. Karst AM, Dai DL, Cheng JQ, Li G. Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival. Cancer Res 2006;66:9221-6.

22. Karbowicz M, Spittle CS, Morrison T, Wu H, Henske EP. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol 2008;128:980-7.

23. Kurschat P, Eming S, Nashan D, Krieg T, Mauch C. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Br J Dermatol 2007;156:653-8.

24. Kirsch M, Winkel H, Pinzer T, Carroll RS, Black PM, Schackert HG, et al. Therapy of hematogenous melanoma metastases with endostatin. Clin Cancer Res 2005;11:1259-67.

25. Mendoza L, Valcarcel M, Carrascal T, Egilegor E, Salado C, Sim BK, et al. Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma metastasis. Cancer Res 2004;64:304-10.

26. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasiis G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.

27. Sim BK, Fogler WE, Zhou HX, Liang H, Madsen JW, Luu K, et al. Zinc ligand-disrupted recombinant human endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 1999;3:41-51.

28. Wu DS, Wu CM, Huang TH, Xie QD. Combined effects of radiotherapy and endostatin gene therapy in melanoma tumor model. Radiat Environ Biophys 2008;47:285-91.

29. Moschos SJ, Oudoux C, Land SR, Agarwala S, Friedland D, Volker KM, et al. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res 2007;17:193-200.

30. Gonzalez-Cao M, Viteri S, Díaz-Lagares A, Gonzalez A, Redondo P, Nieto Y, et al. Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma. Oncology 2008;74:12-6.

31. Varker KA, Biber JE, Kefauver C, Jensen R, Lehman A, Young D, et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007;14:2367-76.

32. Terheyden P, Hofmann MA, Weiningen M, Brocker EB, Becker JC. Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. J Cancer Res Clin Oncol 2007;133:897-901.

33. Eileen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006;95:581-6.

34. Flaherty KT, Schiller J, Schuchter LM, Liu G, Tuveson DA, Redlinger M, et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008;14:4836-42.

35. McDermott DF, Somman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008;26:2178-85.

36. Molhoek KR, Griesemann H, Shu J, Gershwenfeld JE, Brautigan DL, Sluggin CL Jr. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 2008;68:4392-7.

37. Bundschcherer A, Hafner C, Maisch T, Becker B, Landthaler M, Vogt T. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep 2008;19:547-53.

38. Lasithiotakis KG, Sinnberg TW, Schitteck B, Flaherty KT, Kulms D, Maczej E, et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 2008;128:2013-23.

39. Thallinger C, Poeschl W, Pratscher B, Mayerhofer M, Valet P, Tappeiner G, et al. CC1-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotransplantation model. Pharmacology 2007;79:207-13.

40. Chirivi RG, Garofalo A, Crimin MJ, Bawden LJ, Stoppacciaro A, Brown PD, et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994;58:460-4.

41. Quirt I, Bodurth A, Lohmann R, Rusthoven J, Belanger K, Vogt T. Antiproliferative and proapoptotic effects of rapamycin receptor-2. Cancer Res 2008;68:4392-7.

42. Bundschcherer A, Hafner C, Maisch T, Becker B, Landthaler M, Vogt T. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep 2008;19:547-53.

43. Lasithiotakis KG, Sinnberg TW, Schitteck B, Flaherty KT, Kulms D, Maczej E, et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 2008;128:2013-23.

44. Thallinger C, Poeschl W, Pratscher B, Mayerhofer M, Valet P, Tappeiner G, et al. CC1-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotransplantation model. Pharmacology 2007;79:207-13.
44. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, et al. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 2007;30:303-9.

45. Chumsri S, Zhao M, Garofalo M, Burger A, Hamburger A, Zhao F, et al. Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. Leuk Lymphoma 2008;49:359-61.

46. Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC, et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sézary syndrome. Proc Natl Acad Sci U S A 1996;93:9148-53.

47. Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:4293-7.

48. Montaner S, Sodhi A, Pece S, Mesri EA, Gutkind JS. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res 2001;61:2641-8.

49. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, et al. The Kaposi’s sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 2000;60:4873-80.

50. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, He Y, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi’s sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003;3:23-36.

51. Brown LF, Tognazzi K, Dvorak HF, Harrist TJ. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi’s sarcoma and cutaneous angiokeratoma. Am J Pathol 1996;148:1065-74.

52. Cornali E, Zietz C, Benelli R, Weninger W, Masiello L, Breier G, et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi’s sarcoma. Am J Pathol 1996;149:1851-69.

53. Ferrari A, Gomer CJ. Avastin enhances photodynamic therapy treatment of Kaposi’s sarcoma in a mouse tumor model. J Environ Pathol Toxicol Oncol 2006;25:251-9.

54. Gutierrez-Dalmata A, Sanchez-Fructuoso A, Sanz-Guajardo A, Mazuecos A, Franco A, Rial MC, et al. Efficacy of conversion to sirolimus in posttransplantation Kaposi’s sarcoma. Transplant Proc 2005;37:3836-8.

55. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchinson B, Morales JM, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;17:581-9.

56. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005;353:1317-23.

57. Saggar S, Zeichner JA, Brown TT, Phelps RG, Cohen SR. Kaposi’s sarcoma resolves after sirolimus therapy in a patient with pemphigus vulgaris. Arch Dermatol 2008;144:654-7.

58. Guenova E, Metzler G, Hoetzenecker W, Berneburg M, Rocken M. Classic Mediterranean Kaposi’s sarcoma regression with sirolimus. Arch Dermatol 2008;144:692-3.

59. Krown SE. Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 2001;13:374-81.

60. Celestin Schartz NE, Chevret S, Paz C, Kerob D, Verola O, Morel P, et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi’s sarcoma skin lesions: a phase I to II, open-label trial in 17 patients. J Am Acad Dermatol 2008;58:585-91.

61. Rubegni P, Sbano P, De Aloe G, Flori ML, Fimiani M. Thalidomide in the treatment of Kaposi’s sarcoma. Derma- tology 2007;215:240-4.

62. Koontz BF, Miles EF, Rubio MA, Madden JF, Fisher SR, Scher RL, et al. Preoperative radiotherapy and bevaciuzumab for angiosarcoma of the head and neck: two case studies. Head Neck 2008;30:262-6.

63. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med 1999;341:173-81.

64. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994;93:2357-64.

65. Bielenberg DR, Bucana CD, Sanchez R, Mulliken JB, Folkman J, Fidler IJ. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Int J Oncol 1999;14:401-8.

66. Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 2001;159:2271-80.

67. Girotmanolaki A, Avantidou V, Hatzimichael A, Simopoulos C, Sivridis E. The HIF-α/VEGF pathway activation in cutaneous capillary haemangiomas. Pathology 2005;37:149-51.

68. Ritter MR, Dorrell MI, Edmonds J, Friedlander SF, Friedlander M. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci U S A 2002;99:7455-60.

69. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, et al. Inhibition of angiogenesis and murine hemangioma growth by batimatastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995;87:293-8.

70. Vergani V, Garofalo A, Bani MR, Borsotti P, Parker MP, Drudis T. Inhibition of matrix metalloproteinases by over-expression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas. Int J Cancer 2001;91:241-7.

71. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996;56:1324-30.

72. Liekens G, Verbeken E, Vandeputte M, De Clercq E, Neyts J. A novel animal model for hemangiomas: inhibition of heman- gioma development by the angiogenesis inhibitor TNP-470. Cancer Res 1999;59:2376-83.

73. Martinez MI, Sanchez-Carpintero I, North PE, Mihm MC Jr. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002;138:881-4.

74. Welsh O, Olazaran Z, Gomez M, Salas J, Berman B. Treatment of metastatic malignant melanoma. Cancer 2005;103:2584-9.

75. Cornali E, Zietz C, Benelli R, Weninger W, Masiello L, Breier G, et al. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 1996;56:1324-30.

76. Liekens G, Verbeken E, Vandeputte M, De Clercq E, Neyts J. A novel animal model for hemangiomas: inhibition of heman- gioma development by the angiogenesis inhibitor TNP-470. Cancer Res 1999;59:2376-83.

77. Martinez MI, Sanchez-Carpintero I, North PE, Mihm MC Jr. Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol 2002;138:881-4.

78. Welsh O, Olazaran Z, Gomez M, Salas J, Berman B. Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol 2004;51:639-42.

79. Hazen PG, Camey JP, Engstrom CW, Turgeon KL, Reep MD, Tanphaichitr A. Proliferating hemangioma of infancy: successful treatment with topical 5% imiquimod cream. Pediatr Dermatol 2005;22:254-6.
76. Ho NT, Lansang P, Pope E. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J Am Acad Dermatol 2007;56:63-8.
77. McCuaig CC, Dubois J, Powell J, Belleville C, David M, Rousseau E, et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol 2009;26:203-12.
78. Arbiser JL. Efficacy of topical application of eosin for ulcerated hemangiomas. J Am Acad Dermatol 2009;60:350-1.
79. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51.
80. Mentzel T, Beham A, Calonje E, Katenkamp D, Fletcher CD. Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases. Am J Surg Pathol 1997;21:363-74.
81. Lannutti BJ, Gately ST, Quevedo ME, Soff GA, Paller AS. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 1997;57:5277-80.
82. Sidbury R, Neuschler N, Neuschler E, Sun P, Wang XQ, Miller R, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003;121:1205-9.
83. Belmont L, Zemoura L, Couderc LJ. Pulmonary epithelioid haemangioendothelioma and bevacizumab. J Thorac Oncol 2008;3:557-8.
84. Mascarenhas RC, Sanghvi AN, Friedlander L, Geyer SJ, Beasley HS, Van Thiel DH. Thalidomide inhibits the growth and progression of hepatic epithelial hemangioendothelioma. Oncology 2004;67:471-5.
85. Perry B, Banyard J, McLaughlin ER, Watnick R, Sohn A, Brindley DN, et al. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol 2007;143:504-6.
86. Marler JJ, Fishman SJ, Kifroy SM, Fang J, Upton J, Mulliken JB, et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics 2005;116:38-45.
87. Vikkula M, Boon LM, Carraway KL 3rd, Calvert JT, Gately ST, Quevedo ME, Soff GA, Paller AS. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 1997;57:5277-80.
88. Sidbury R, Neuschler N, Neuschler E, Sun P, Wang XQ, Miller R, et al. Topically applied imiquimod inhibits vascular tumor growth in vivo. J Invest Dermatol 2003;121:1205-9.
89. Phung TL, Oble DA, Jia W, Benjamin LE, Mihm MC Jr, Nelson JS. Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of pulsed dye laser and topical imiquimod versus laser alone for treatment of port wine stain birthmarks. Lasers Surg Med 2008;40:605-10.
90. Wolf JE Jr, Hubler WR Jr. Tumor angiogenic factor and human skin tumors. Arch Dermatol 1975;111:321-7.
91. Ribatti D, Vaccar L, Schiraldi G, Sorino S, Caprio F, Mazzotta F, et al. Pyogenic granuloma stimulates angiogenesis in the chick embryo chorioallantoic membrane. Int J Microcirc Clin Exp 1996;16:82-8.
92. Yuan K, Jin YT, Lin MT. Expression of Tie-2, angiopoietin-1, angiopoietin-2, ephrinB2 and EphB4 in pyogenic granuloma of human gingiva implicates their roles in inflammatory angiogenesis. J Periodontal Res 2000;35:165-71.
93. Yuan K, Jin YT, Lin MT. The detection and comparison of angiogenesis-associated factors in pyogenic granuloma by immunohistochemistry. J Periodontal Res 2000;7:701-9.
94. Saarialho-Kere UK, Chang ES, Welsch HG, Parks WC. Distinct localization of collagenase and tissue inhibitor of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma. J Clin Invest 1992;90:1952-7.
95. Shimizu K, Naito S, Urata Y, Sekine I, Kondo T, Katayama I. Inducible nitric oxide synthase is expressed in granuloma pyogenicum. Br J Dermatol 1998;138:769-73.
96. Li VW, Li WW, Talcott KE, Zhao AW. Imiquimod as an antiangiogenic agent. J Drugs Dermatol 2005;4:708-17.
97. Ezzell TJ, Formowitz JS, Ramos-Caro FA. Recurrent pyogenic granuloma treated with topical imiquimod. J Am Acad Dermatol 2006;54:5244-5.
98. Fallah H, Fischer G, Zagaraless S. Pyogenic granuloma in children: treatment with topical imiquimod. Australas J Dermatol 2007;48:217-20.
99. Georgiou S, Monastirli A, Pasmatsu E, Tsambaos D. Pyogenic granuloma: complete remission under occlusive imiquimod 5% cream. Clin Exp Dermatol 2008;33:454-6.
100. Goldenberg G, Krowchuk DP, Jorizzo JL. Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream. J Dermatolog Treat 2006;17:121-3.
101. Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 2002;4:48-48.
102. Potter C, Pedraza LG, Xu T. Akt regulates growth by phosphorylating Tsc2. Nat Cell Biol 2002;4:658-65.
103. Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 2002;4:699-704.
104. Schwartz RA, Fernandez G, Kotulska K, Joziwka S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007;57:189-202.
105. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. Tsc tumors in tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007;57:189-202.
106. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. Tsc tumors in tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 2007;57:189-202.
113. Hofbauer GF, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wuthrich RP, et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 2008;159:473-5.

114. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994;180:1141-6.

115. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999;141:1054-60.

116. Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD, Rudge JS. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003;102:161-8.

117. Man XY, Yang XH, Cai SQ, Bu ZY, Zheng M. Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J Cell Mol Med 2008;12:649-60.

118. Krueger G, Ellis CN. Psoriasis—recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005;53:594-100.

119. Nickoloff BJ, Mitra RS, Varani J, Dixo VM, Polverini PJ. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994;144:820-8.

120. Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 2001;116:713-20.

121. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Kuroda K, et al. Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.

122. Reitamo S, Spuls P, Sassolas B, Lahfa M, Cludy A, Griffiths CE. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001;145:438-45.

123. Ormerod AD, Shah SA, Copeland P, Omar G, Winfield A. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 2005;152:758-64.

124. Quesada AR, Munoz-Chapuli R, Medina MA. Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 2006;26:483-530.

125. Keshtgarpour M, Dudek AZ. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res 2007;149:103-6.

126. Cuevas P, Arrazola JM. Dobesilate in the treatment of plaque psoriasis. Eur J Dermatol Res 2005;10:454-6.

127. Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 2001;117:977-83.

128. Chen L, Lin SX, Overbergh L, Mathieu C, Chan LS. The disease progression in the keratin 14 IL-4 transgenic mouse model of atopic dermatitis parallels the up-regulation of B cell activation molecules, proliferation and surface and serum IgE. Clin Exp Immunol 2005;142:21-30.

129. Chen L, Martinez O, Overbergh L, Mathieu C, Prabhakar BS, Chan LS. Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin Exp Immunol 2004;138:375-87.

130. Chen L, Martinez O, Venkataramani P, Lin SX, Prabhakar BS, Chan LS. Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis. Clin Exp Immunol 2005;139:189-201.

131. Di Nardo A, Vitiello A, Gallo RL. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 2003;170:2274-8.

132. Braff MH, Bardan A, Nizet V, Gallo RL. Cutaneous defense mechanisms by antimicrobial peptides. J Invest Dermatol 2005;125:9-13.

133. Deindl E, Kupatt C, editors. Therapeutic neovascularization: quo vadis? New York: Springer-Verlag; 2007.

134. Rodriguez-Martinez S, Cancino-Diaz JC, Vargas-Zuniga LM, Cancino-Diaz ME. LL-37 regulates the overexpression of vascular endothelial growth factor (VEGF) and c-IAP-2 in human keratinocytes. Int J Dermatol 2008;47:457-62.

135. Yamasaki K, Di Nardo A, Bardan A, Murakami M, Ohtake T, Coda A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007;13:975-80.

136. Cuevas P, Arrazola JM. Therapeutic response of rosacea to dobesilate. Eur J Med Res 2005;10:454-6.

137. Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 2001;117:977-83.

138. Chen L, Lin SX, Overbergh L, Mathieu C, Chan LS. The disease progression in the keratin 14 IL-4 transgenic mouse model of atopic dermatitis parallels the up-regulation of B cell activation molecules, proliferation and surface and serum IgE. Clin Exp Immunol 2005;142:21-30.

139. Chen L, Martinez O, Overbergh L, Mathieu C, Prabhakar BS, Chan LS. Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin Exp Immunol 2004;138:375-87.

140. Chen L, Martinez O, Venkataramani P, Lin SX, Prabhakar BS, Chan LS. Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis. Clin Exp Immunol 2005;139:189-201.

141. Agha-Majzoub R, Becker RP, Schraufnagel DE, Chan LS. Angiogenesis: the major abnormality of the keratin-14 IL-4 transgenic mouse model of atopic dermatitis. Microcirculation 2005;12:455-76.

142. Chen L, Marble DJ, Agha R, Peterson JD, Becker RP, Jin T, et al. The progression of inflammation parallels the dermal angiogenesis in a keratin 14 IL-4 transgenic model of atopic dermatitis. Microcirculation 2008;15:49-64.

143. Zhang Y, Matsuo H, Morita E. Increased production of vascular endothelial growth factor (VEGF) and c-IAP-2 in human keratinocytes. Int J Dermatol 2005;44:90-7.

144. Wienes DV, et al. Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts. Am J Physiol Cell Physiol 2004;286:C905-12.
148. Ong CT, Khoo YT, Tan EK, Mukhopadhyay A, Do DV, Han HC, et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. J Pathol 2007;211:95-108.

149. Goren I, Müller E, Schiefelbein D, Gutwein P, Seitz O, Pfeilschifter J, et al. Akt1 controls insulin-driven VEGF biosynthesis from keratinocytes: implications for normal and diabetes-impaired skin repair in mice. J Invest Dermatol 2009;129:752-64.

150. Cheng B, Liu H, Fu X, Sheng Z, Sun T. Recombinant human platelet-derived growth factor enhances repair of cutaneous full-thickness excision by increasing the phosphorylation of extracellular signal-regulated kinase in diabetic rat. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2006;20:1093-8.

151. Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg 2006;117(7 suppl):1435-95.